Once a red-hot ingredient, cannabidiol (CBD) seeks to retake the supplement spotlight after a rocky 2020, led by new hemp-derived phytocannabinoids and other derivatives. Market saturation and regulatory uncertainty has hampered industry growth, but research on the endocannabinoid system is connecting CBD intake and various health issues, from inflammation to mood and beyond. Other minor phytocannabinoids identified for more in-depth research include cannabigerol (CBG), cannabinol (CBN) and cannabichromene (CBC).

May 13, 2021

1 Min Read
NPI21-CBD-DM-1540x800.jpg

Takeaways for your business:

• Much remains to be known about the effect of phytocannabinoids on the endocannabinoid system (ECS).
• Cannabinoids with targeted therapeutic promise could drive consumer self-care market expansion.
• Delta-8 THC is on the rise as a psychoactive alternative to THC, and the sports market is watching.

NPI21-CBD-Logos.jpg

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like